Takagi H - Search Results

1

Prediction of effect of interferon on chronic hepatitis C.

Takagi H, Takehara K, Shimoda R, Kakizaki S, Takayama H, Abe T, Yamada T, Hashimoto Y, Saitoh S, Matsumoto T, Kojima A, Takezawa J, Yuasa K, Moriguchi M, Sekiguchi T, Nagamine T, Mori M. Takagi H, et al. Dig Dis Sci. 1997 Nov;42(11):2270-6. doi: 10.1023/a:1018866717753. Dig Dis Sci. 1997. PMID: 9398805

2

The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatitis C patients.

Nagamine T, Takagi H, Hashimoto Y, Takayama H, Shimoda R, Nomura N, Suzuki K, Mori M, Nakajima K. Nagamine T, et al. Among authors: takagi h. Biol Trace Elem Res. 1997 Jul-Aug;58(1-2):65-76. doi: 10.1007/BF02910667. Biol Trace Elem Res. 1997. PMID: 9363321

3

Quantitative analysis of hepatitis B virus precore mutant in hepatitis type B.

Ichikawa T, Takagi H, Kinoshita M, Shimoda R, Nagamine T, Mori M. Ichikawa T, et al. Among authors: takagi h. Tohoku J Exp Med. 1998 Dec;186(4):323-33. doi: 10.1620/tjem.186.323. Tohoku J Exp Med. 1998. PMID: 10328164 Free article. Clinical Trial.

4

HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C.

Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. Kakizaki S, et al. Among authors: takagi h. J Hepatol. 1999 May;30(5):794-800. doi: 10.1016/s0168-8278(99)80131-7. J Hepatol. 1999. PMID: 10365804

5

[Autoimmune thyroid disease induced by interferon therapy].

Murakami M, Kakizaki S, Takayama H, Takagi H, Mori M. Murakami M, et al. Among authors: takagi h. Nihon Rinsho. 1999 Aug;57(8):1779-83. Nihon Rinsho. 1999. PMID: 10483250 Review. Japanese.

6

Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.

Kakizaki S, Takagi H, Yamada T, Ichikawa T, Abe T, Sohara N, Kosone T, Kaneko M, Takezawa J, Takayama H, Nagamine T, Mori M. Kakizaki S, et al. Among authors: takagi h. J Viral Hepat. 1999 Jul;6(4):315-9. doi: 10.1046/j.1365-2893.1999.00168.x. J Viral Hepat. 1999. PMID: 10607246 Clinical Trial.

7

Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C.

Toyoda M, Kakizaki S, Horiguchi N, Sato K, Takayama H, Takagi H, Nagamine T, Mori M. Toyoda M, et al. Among authors: takagi h. Liver. 2000 Jul;20(4):305-11. doi: 10.1034/j.1600-0676.2000.020004305.x. Liver. 2000. PMID: 10959809

8

Histological change after interferon therapy in chronic hepatitis C in view of iron deposition in the liver.

Kakizaki S, Takagi H, Ichikawa T, Abe T, Yamada T, Suzuki K, Kojima A, Takayama H, Takezawa J, Nagamine T, Mori M. Kakizaki S, et al. Among authors: takagi h. Biol Trace Elem Res. 2000 Feb;73(2):151-62. doi: 10.1385/BTER:73:2:151. Biol Trace Elem Res. 2000. PMID: 11049207 Clinical Trial.

9

Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b.

Nagamine T, Takagi H, Takayama H, Kojima A, Kakizaki S, Mori M, Nakajima K. Nagamine T, et al. Among authors: takagi h. Biol Trace Elem Res. 2000 Summer;75(1-3):53-63. doi: 10.1385/BTER:75:1-3:53. Biol Trace Elem Res. 2000. PMID: 11051596 Clinical Trial.

10

Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C.

Takagi H, Nagamine T, Abe T, Takayama H, Sato K, Otsuka T, Kakizaki S, Hashimoto Y, Matsumoto T, Kojima A, Takezawa J, Suzuki K, Sato S, Mori M. Takagi H, et al. J Viral Hepat. 2001 Sep;8(5):367-71. doi: 10.1046/j.1365-2893.2001.00311.x. J Viral Hepat. 2001. PMID: 11555194 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,624 results

Search Page

Filters